EFFECT OF TAMOXIFEN ON PLASMA LIPID PROFILE IN PATIENTS OF BREAST CANCER
DOI:
https://doi.org/10.55519/JAMC-04-7330Abstract
Background: To evaluate the effect of Tamoxifen on plasma lipid profile in breast cancer patients presenting at tertiary care hospital. Methods: It was a longitudinal study conducted at the department of oncology of Jinnah Postgraduate Medical Center from December 2018 to November 2019. Eighty-eight females of age 26–66 years diagnosed with breast cancer were included in the study using non-probability consecutive sampling technique. Detailed gynaecological and clinical investigations and detailed history were taken. The blood samples of all the patients were collected and plasma lipid profile was measured before initiation of Tamoxifen treatment and three- and six-months post treatment at clinical laboratory. The plasma lipid profile includes the measurement of Total cholesterol (mg/dl), Triglyceride(mg/dl), High density Lipoprotein (mg/dl) & Low-density Lipoprotein (mg/dl). SPSS version 23 was used to analyse data. Results: After treatment there was significant reduction in serum cholesterol & Low-density Lipoprotein level by 20.54 mg/dl & 16.46 mg/dl at 3 months (p<0.05), moreover there was significant increase in Triglyceride by 22.14 at 3 months (p<0.05). No significant difference was observed in High density lipoprotein level at 3-months after using Tamoxifen. At 6 months there was significant reduction in serum cholesterol & Low-density lipoprotein by 32.29mg/dl and 24.11 mg/dl at 6 months (p<0.05), moreover there was significant increase in Triglyceride level by 42.19 mg/dl at 6 months (p<0.05). No significant difference was observed in High density lipoprotein level at 6 months after using Tamoxifen. Conclusion: Total cholesterol and Low-density Lipoprotein levels showed significant reduction over the period of six months from the baseline with the use of Tamoxifen. Hence Tamoxifen should be considered to have an added advantage on lipid metabolism and therefore, can reduce the risk of cardiovascular events.References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66(1):7–30.
Li X, Liu ZL, Wu YT, Wu H, Dai W, Arshad B, et al. Status of lipid and lipoprotein in female breast cancer patients at initial diagnosis and during chemotherapy. Lipids Health Dis 2018;17(1):91.
Gupta S, Tandon VR, Kapoor B, Gupta A, Gupta GD, Khajuria V. Effects of tamoxifen therapy on plasma lipid profile in patients of breast cancer. J Assoc Physicians India 2006;54:183–6.
Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353(17):1784–92.
Wolff AC, Davidson NE. Use of SERMs for the adjuvant therapy of early-stage breast cancer. Ann N Y Acad Sci 2001;949:80–8.
Ali ZAM, Jasim WK, Hussein DZ, Alnaqas MA. Tamoxifen Effects on the lipid profile in premenopausal women with Breast cancer: A follow up study. J Fac Med Bagdad 2018;60(3):141–4.
Atalay G, Dirix L, Biganzoli L, Beex L, Nooij M, Cameron D, et al. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. Ann Oncol 2004;15(2):211–7.
Bruning PF, Bonfrer JM, Hart AA, de Jong-Bakker M, Linders D, van Loon J, et al. Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer 1988;58(4):497–9.
Caleffi M, Fentiman IS, Clark GM, Wang DY, Needham J, Clark K, et al. Effect of tamoxifen on oestrogen binding, lipid and lipoprotein concentrations and blood clotting parameters in premenopausal women with breast pain. J Endocrinol 1988;119(2):335–9.
Grey AB, Stapleton JP, Evans MC, Reid IR. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 1995;80(11):3191–5.
Joensuu H, Holli K, Oksanen H, Valavaara R. Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. Breast Cancer Res Treat 2000;63(3):225–34.
Kusama M, Miyauchi K, Aoyama H, Sano M, Kimura M, Mitsuyama S, et al. Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer. Breast Cancer Res Treat 2004;88(1):1–8.
Sharma D, Sharma U, Bhatnagar VB, Singh VS. A comparative of the effect of tamoxifen on serum lipid and lipoprotein profile in premenopausal & postmenopausal women with breast carcinoma & associated risk of vascular complication. Indian J Med Sci 2001;55(1):37–42.
Decensi A, Gandini S, Guerrieri-Gonzaga A, Johansson H, Manetti L, Bonanni B, et al. Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. J Clin Oncol 1999;17(9):2633–8.
Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and Mortality and Epidemiology of Breast Cancer in the World. Asian Pac J Cancer Prev 2016;17(S3):43–6.
Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 1991;83(20):1450–9.
Anjum F, Razvi N, Masood MA. Breast cancer therapy: a mini review. MOJ Drug Des Develop Ther 2017;1(2):35–8.
Lin C, Chen LS, Kuo SJ, Chen DR. Adjuvant tamoxifen influences the lipid profile in breast cancer patients. Breast care (Basel) 2014;9(1):35–9.
Esteva FJ, Hortobagyi GN. Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women. Breast 2006;15(3):301–12.
Lewis S. Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women? Am Heart J 2007;153(2):182–8.
Markopoulos C, Polychronis A, Zobolas V, Xepapadakis G, Papadiamantis J, Koukouras D, et al. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast Cancer Res Treat 2005;93(1):61–6.
Hozumi Y, Kawano M, Hakamata Y, Miyata M, Jordan VC. Tamoxifen inhibits lipoprotein activity: in vivo and in vitro studies. Horm Res 2000;53(1):36–9.
Tsoupras A, Lordan R, Zabetakis I. Inflammation, not Cholesterol, Is a Cause of Chronic Disease. Nutrients 2018;10(5):604.
Goetz MP, Suman VJ, Reid JM, Northfelt DW, Mahr MA, Ralya AT, et al. First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer. J Clin Oncol 2017;35(30):3391–400.
Gopinath M, Premaletha T. Effects of tamoxifen on lipid profile, serum calcium and gonadotropin levels in carcinoma breast patients. J Evol Med Dent Sci 2017;6(31):2507–12.
Gaibar M, Fernandez G, Romero-Lorca A, Novillo A, Tejerina A, Bandres F, et al. Tamoxifen therapy in breast cancer: do apolipoprotein E genotype and menopausal state affect plasma lipid changes induced by the drug? Int J Biol Markers 2013;28(4):e371–6.
Hong N, Yoon HG, Seo DH, Park S, Kim SI, Sohn JH, et al. Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study. Eur J Cancer 2017;82:103–14.
Hackshaw A, Roughton M, Forsyth S, Monson K, Reczko K, Sainsbury R, et al. Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. J Clin Oncol 2011;29(13):1657–63.
Ferreira A, Paci A, Meglio AD, André F, Everhard S, Martin A, et al. 93O Impact of tamoxifen (TAM) serum concentration on side effects among premenopausal patients (pts) with early breast cancer (BC) in the prospective multicenter CANTO cohort. Ann Oncol 2019;30(Suppl_3):mdz096.
Pritchard KI. Patient education: Early-stage breast cancer treatment in postmenopausal women (Beyond the Basics) 2017. [Internet]. [cited 2020 May]. Available from: https://www.uptodate.com/contents/early-stage-breast-cancer-treatment-in-postmenopausal-women-beyond-the-basics
Lorizio W, Wu AH, Beattie MS, Rugo H, Tchu S, Kerlikowske K, et al. Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat 2012;132(3):1107–18.
Additional Files
Published
Issue
Section
License
Copyright (c) 2023 Journal of Ayub Medical College Abbottabad
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
